Ann: RC220 Meets Quality Specifications, page-72

I figured this put any speculative $$$ application of RC110 to bed?

I don't think RC110 will have much of a part to play moving forward - even Sheba 3.0 (if it happens) would likely be utilising RC220. I don't believe RAC's current funds are enough to get us to a transaction - however I DO believe they're enough to get us to an alternative source of funding, beyond the traditional CR.

As mentioned before RAC could partner in the AML space with either Abbvie or Otsuka which will keep the lights on and the AML program ticking forwards. The big question is whether this will also support the Cardio/FTO program to Phase 2. In truth I was hoping for a better market reaction to Sheba 2.0 - but in reality it was just another confirmation of what the market has long priced in:

1) Bisantrene is very safe
2) Bisantrene has clinically significant anti-cancer properties.

It's great we also got circumstantial evidence of cardio-protection (and even maybe some FTO data if we're lucky come Dec 11) but we're comfortably beyond any serious clinical risk, and 2023 has landed us firmly in the territory of executive risk. We need a robust clinical strategy AND a detailed commercial strategy, as we saw with the DCB-Strategy leaving the $$ up for speculation was not a good move. The New-New-Strategy^TM will need to be both very financially conservative and sufficiently transparent, no guesswork needed. I believe RAC understand this, and I'm hopeful for a strong strategy and focused management.

This evolved beyond a simple response to your post John, forgive me for rambling.